Effect of metformin on serum interleukin-6 levels in polycystic ovary syndrome: A systematic review

BMC Women's Health

Volumn 14, Issue 1, 2014, Pages

  Xu, Xinghua ^a   Du, Chigang ^a   Zheng, Qingmei ^b   Peng, Lina ^a   Sun, Yuanyuan ^c  

^a LIAOCHENG PEOPLE'S HOSPITAL   (China)

^b QINGDAO UNIVERSITY   (China)

^c Department of Gynecology and Obstetrics Dongchangfu District Maternal and Child Health Hospital   (China)

Author keywords

Chronic inflammation; Interleukin 6; Metformin; Polycystic ovary syndrome

Indexed keywords

INSULIN; INTERLEUKIN 6; METFORMIN; ANTIDIABETIC AGENT; IL6 PROTEIN, HUMAN;

ARTICLE; DRUG EFFECT; HUMAN; INSULIN METABOLISM; OVARY POLYCYSTIC DISEASE; PROTEIN BLOOD LEVEL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; BLOOD; FEMALE; INFLAMMATION; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME;

FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN RESISTANCE; INTERLEUKIN-6; METFORMIN; POLYCYSTIC OVARY SYNDROME;

EID: 84906842461     PISSN: None     EISSN: 14726874     Source Type: Journal    
DOI: 10.1186/1472-6874-14-93     Document Type: Article

References (21)

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004, 89:2745-2749.
2. Xu X, Shi Y, Cui Y, Ma J, Che L, Chen ZJ. Endocrine and metabolic characteristics of polycystic ovary syndrome in Chinese women with different phenotypes. Clin Endocrinol (Oxf) 2012, 76:425-430.
3. Xu X, Zhao H, Shi Y, You L, Bian Y, Zhao Y, Chen ZJ. Family association study between INSR gene polymorphisms and PCOS in Han Chinese. Reprod Biol Endocrinol 2011, 9:76.
4. Tumu VR, Govatati S, Guruvaiah P, Deenadayal M, Shivaji S, Bhanoori M. An interleukin-6 gene promoter polymorphism is associated with polycystic ovary syndrome in South Indian women. J Assist Reprod Genet 2013, 30:1541-1546.
5. Mohlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AF, Schill T, Schlosser HW, Brabant G, Schofl C. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004, 150:525-532.
6. Lin YS, Tsai SJ, Lin MW, Yang CT, Huang MF, Wu MH. Interleukin-6 as an early chronic inflammatory marker in polycystic ovary syndrome with insulin receptor substrate-2 polymorphism. Am J Reprod Immunol 2011, 66:527-533.
7. Escobar-Morreale HF, Calvo RM, Villuendas G, Sancho J, San Millan JL. Association of polymorphisms in the interleukin 6 receptor complex with obesity and hyperandrogenism. Obes Res 2003, 11:987-996.
8. Gonzalez F, Sia CL, Stanczyk FZ, Blair HE, Krupa ME. Hyperandrogenism exerts an anti-inflammatory effect in obese women with polycystic ovary syndrome. Endocrine 2012, 42:726-735.
9. Diamanti-Kandarakis E, Paterakis T, Kandarakis HA. Indices of low-grade inflammation in polycystic ovary syndrome. Ann N Y Acad Sci 2006, 1092:175-186.
10. Dunaif A. Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome-a reappraisal. Nat Clin Pract Endocrinol Metab 2008, 4:272-283.
11. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 2013, 6:1-13.
12. Escobar-Morreale HF, Carmina E, Dewailly D, Gambineri A, Kelestimur F, Moghetti P, Pugeat M, Qiao J, Wijeyaratne CN, Witchel SF, Norman RJ. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 2012, 18:146-170.
13. Rotterdam EA-SP. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004, 19:41-47.
14. Azziz R. Diagnostic criteria for polycystic ovary syndrome: a reappraisal. Fertil Steril 2005, 83:1343-1346.
15. Ibanez L, de Zegher F. Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. J Clin Endocrinol Metab 2005, 90:39-43.
16. Luque-Ramirez M, Escobar-Morreale HF. Treatment of polycystic ovary syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with the decrease of serum interleukin-6 concentrations. Horm Metab Res 2010, 42:815-820.
17. Jakubowska J, Bohdanowicz-Pawlak A, Milewicz A, Szymczak J, Bednarek-Tupikowska G, Demissie M. Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment. Gynecol Endocrinol 2008, 24:378-384.
18. Ciaraldi TP, Aroda V, Mudaliar SR, Henry RR. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: Effects of pioglitazone and metformin treatment. Metabolism 2013, 62:1587-1596.
19. Ojeda-Ojeda M, Murri M, Insenser M, Escobar-Morreale HF. Mediators of low-grade chronic inflammation in polycystic ovary syndrome (PCOS). Curr Pharm Des 2013, 19:5775-5791.
20. Ibanez L, Valls C, Marcos MV, Ong K, Dunger DB, De Zegher F. Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: effects of prepubertal initiation and postpubertal discontinuation of metformin treatment. J Clin Endocrinol Metab 2004, 89:4331-4337.
21. Gozdemir E, Kaygusuz I, Kafali H. Is hepcidin a new cardiovascular risk marker in polycystic ovary syndrome?. Gynecol Obstet Invest 2013, 75:196-202.